<DOC>
	<DOCNO>NCT01078545</DOCNO>
	<brief_summary>The purpose study determine influence GnRH ( gonadotropin release hormone ) analogue - Lucrin Depot 11.25 mg ( Lucrin Depot 3.75mg - Ukraine ) administration intensity lower urinary tract symptom ( LUTS ) patient diagnose locally advanced and/or metastatic prostate cancer LUTS .</brief_summary>
	<brief_title>Lucrin速 Depot Efficacy Safety Monitoring Study Patients With Advanced Prostate Cancer Lower Urinary Tract Symptoms ( LUTS )</brief_title>
	<detailed_description>The remain target : - ass intensity LUTS Polish Ukrainian patient locally advance metastatic prostate cancer , previously untreated hormonal therapy</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Age &gt; 50 year Locally advance ( T3T4 ) and/or metastatic ( N+/M+ ) hormonesensitive prostate cancer , confirm histological examination Presence low urinary tract symptom ( LUTS ) IPSS &gt; 0 Treatment Lucrin速 Depot routine therapy patient . The decision Lucrin速 Depot choice associate patient 's participation study , result best medical knowledge practice . Until inclusion PMOS patient treat GnRH analogue . The patient , inclusion study , treat surgery ( radical prostatectomy ) . Patients include study contraindication treatment Lucrin速 Depot exist , treatment option , accord present medical knowledge , potentially beneficial patient . Physician patient stop treatment moment , indication reason exist .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Lower urinary tract symptom</keyword>
	<keyword>Hormonotherapy</keyword>
	<keyword>LHRH analogue</keyword>
	<keyword>Androgen deprivation therapy ( ADT )</keyword>
</DOC>